Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD1 Antibody”

602 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 602 results

Testing effectiveness (Phase 2)UnknownNCT05138146
What this trial is testing

Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

Who this might be right for
Sarcoma, Soft Tissue
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 70
Early research (Phase 1)Study completedNCT04047862
What this trial is testing

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Locally Advanced and Metastatic Solid Tumors
BeiGene 446
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Study completedNCT03623854
What this trial is testing

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Who this might be right for
ChordomaLocally Advanced ChordomaMetastatic Chordoma+1 more
Jonsson Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Testing effectiveness (Phase 2)UnknownNCT04303741
What this trial is testing

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Testing effectiveness (Phase 2)UnknownNCT05311566
What this trial is testing

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Who this might be right for
Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1+6 more
Lei Li 92
Testing effectiveness (Phase 2)Looking for participantsNCT06393361
What this trial is testing

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Who this might be right for
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital 100
Early research (Phase 1)Ended earlyNCT05904496
What this trial is testing

BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 44
Early research (Phase 1)Study completedNCT03287427
What this trial is testing

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

Who this might be right for
Colorectal CancerAdenoid Cystic Carcinoma
Peter MacCallum Cancer Centre, Australia 27
Not applicableUnknownNCT06281912
What this trial is testing

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients

Who this might be right for
Early MelanomaAdvanced Melanoma
Azienda Ospedaliera di Perugia 70
Testing effectiveness (Phase 2)UnknownNCT05723432
What this trial is testing

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Shanghai Kanda Biotechnology Co., Ltd. 84
Early research (Phase 1)UnknownNCT05225116
What this trial is testing

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Who this might be right for
Hepatocellular Carcinoma
Beijing Tsinghua Chang Gung Hospital 20
Early research (Phase 1)Ended earlyNCT05859464
What this trial is testing

ZL-1218 in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid Tumor
Zai Lab (Hong Kong), Ltd. 34
Testing effectiveness (Phase 2)Study completedNCT04068519
What this trial is testing

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Who this might be right for
Advanced Solid Tumors
BeiGene 300
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Early research (Phase 1)Active Not RecruitingNCT04042701
What this trial is testing

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Who this might be right for
Breast CancerNon-small Cell Lung Carcinoma
Daiichi Sankyo 115
Not applicableUnknownNCT04889768
What this trial is testing

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Who this might be right for
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
Zhejiang Cancer Hospital 46
Testing effectiveness (Phase 2)Study completedNCT04868708
What this trial is testing

AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Akeso 50
Not applicableLooking for participantsNCT07586891
What this trial is testing

Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma

Who this might be right for
Melanoma (Skin Cancer)
Xijing Hospital 80
Load More Results